Skip to content

PANDA (Prospective Assessments with Neuroimaging and fluid Data Analysis in Parkinson's disease) study : Unraveling Parkinson's Disease Subtypes - Rationale and Protocol

PANDA (Prospective Assessments with Neuroimaging and fluid Data Analysis in Parkinson's disease) study : Unraveling Parkinson's Disease Subtypes - Rationale and Protocol

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091709
Enrollment
Unknown
Registered
2024-11-01
Start date
2024-09-24
Completion date
Unknown
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Healthy control group:None

Sponsors

Guangdong Provincial People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for Parkinson's disease group: 1. Patients with primary Parkinson's disease diagnosed by two or more senior neurologists according to the MDS diagnostic criteria 2. Age: 40-80 years old, the first motor symptoms appeared after 40 years old 3. Participants and their families fully understood and signed the informed consent form Inclusion criteria for healthy control group: 1. Global cognitive assessment: MMSE = 26, MoCA = 24 2. Age: 40 - 80 years old 3. Able to complete a comprehensive neuropsychological assessment without self-reported cognitive decline 4. Participants and their families fully understood and signed the informed consent form

Exclusion criteria

Exclusion criteria: Exclusion criteria for Parkinson's disease group: 1. Use of anticholinergic drugs 2. Clinically significant lesions found in previous cranial MRI or EEG scans 3. Schizophrenia, delirium or hallucinations that affect clinical evaluation 4. After deep brain stimulation surgery 5. Combined autoimmune or infectious diseases and other medical diseases that affect clinical evaluation Exclusion criteria for healthy control group: 1. Abnormal cognitive function (MMSE < 26, MoCA < 24) 2. Clinically significant lesions found in previous MRI or EEG scans 3. Combined schizophrenia, delirium or hallucinations 4. Previous brain surgery or severe trauma 5. Recent use of cholinesterase inhibitors or other drugs 6. Autoimmune or infectious diseases 7. The patient or his/her immediate family members are diagnosed with neurodegenerative diseases

Design outcomes

Primary

MeasureTime frame
inflammatory protein in body fluid;the change of brain stucture;

Secondary

MeasureTime frame
Eye movement indicators;24-hour ambulatory blood pressure;Gait assessment;the change of fundus oculi;

Countries

China

Contacts

Public ContactYuhu Zhang

Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences)

yhzhangsd@126.com+86 20 8382 7812

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026